Scher HI - Search Results

1

The long tail of oncogenic drivers in prostate cancer.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, Sboner A, Zafeiriou Z, Miranda S, Bielski CM, Penson AV, Tolonen C, Huang FW, Robinson D, Wu YM, Lonigro R, Garraway LA, Demichelis F, Kantoff PW, Taplin ME, Abida W, Taylor BS, Scher HI, Nelson PS, de Bono JS, Rubin MA, Sawyers CL, Chinnaiyan AM; PCF/SU2C International Prostate Cancer Dream Team; Schultz N, Van Allen EM. Armenia J, et al. Among authors: scher hi. Nat Genet. 2018 May;50(5):645-651. doi: 10.1038/s41588-018-0078-z. Epub 2018 Apr 2. Nat Genet. 2018. PMID: 29610475 Free PMC article.

2

Chemotherapy for muscle-infiltrating bladder cancer.

Scher HI, Kantoff PW. Scher HI, et al. Hematol Oncol Clin North Am. 1992 Feb;6(1):169-78. Hematol Oncol Clin North Am. 1992. PMID: 1556048 Review.

3

Chemotherapy for metastatic bladder cancer.

Kantoff PW, Scher HI. Kantoff PW, et al. Among authors: scher hi. Hematol Oncol Clin North Am. 1992 Feb;6(1):195-203. Hematol Oncol Clin North Am. 1992. PMID: 1556050 Review.

4

Introduction: prostate cancer.

Scher HI. Scher HI. Semin Oncol. 1994 Oct;21(5):511-3. Semin Oncol. 1994. PMID: 7939744 No abstract available.

5

Prostate cancer: how can a common disease be so controversial?

Kelly WK, Scher HI. Kelly WK, et al. Among authors: scher hi. Curr Opin Oncol. 1994 May;6(3):318-31. Curr Opin Oncol. 1994. PMID: 8080862 Review.

6

Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma.

Ghossein RA, Rosai J, Scher HI, Seiden M, Zhang ZF, Sun M, Chang G, Berlane K, Krithivas K, Kantoff PW. Ghossein RA, et al. Among authors: scher hi. Urology. 1997 Jul;50(1):100-5. doi: 10.1016/S0090-4295(97)00127-1. Urology. 1997. PMID: 9218026

7

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study.

Konety BR, Eastham JA, Reuter VE, Scardino PT, Donat SM, Dalbagni G, Russo P, Herr HW, Schwartz L, Kantoff PW, Scher H, Kelly WK. Konety BR, et al. J Urol. 2004 Feb;171(2 Pt 1):709-13. doi: 10.1097/01.ju.0000108122.36893.5a. J Urol. 2004. PMID: 14713792 Clinical Trial.

8

Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.

Ross RW, Manola J, Hennessy K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW. Ross RW, et al. Clin Cancer Res. 2005 Jul 15;11(14):5195-8. doi: 10.1158/1078-0432.CCR-05-0431. Clin Cancer Res. 2005. PMID: 16033836

9

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP. Chen Z, et al. Among authors: scher hi. Nature. 2005 Aug 4;436(7051):725-30. doi: 10.1038/nature03918. Nature. 2005. PMID: 16079851 Free PMC article.

10

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Scher HI, Sawyers CL. Scher HI, et al. J Clin Oncol. 2005 Nov 10;23(32):8253-61. doi: 10.1200/JCO.2005.03.4777. J Clin Oncol. 2005. PMID: 16278481 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

685 results

Search Page